CHANGES IN DIURNAL AND NOCTURNAL MELATONIN LEVEL IN WOMEN WITH METABOLIC SYNDROME STRATIFIED BY THE CONCENTRATION OF SERUM TRIGLICERIDES AND HIGHT DENSITY LIPOPROTEIN CHOLESTEROL CONCENTRATION
Keywords:
melatonin, leptin, ghrelin, metabolic syndrome, womenAbstract
Metabolic syndrome (MetS) is defined as a constellation of interrelated metabolic risk factors that increase the risk of developing type 2 diabetes mellitus and cardiovascular disease. According to the definitions of a number of international organizations and expert groups of MetS, dyslipidaemia is always indicated as one of the main risk factor.
Objective: To compare the night and day concentrations of the hormonal parameters melatonin, leptin, ghrelin in women with MetS and we analyse their relationship according to the concentration of high-density lipoprotein (HDL)-cholesterol and the concentration of triglyceride (TG).
Methods: 41 women with diagnosis MetS according to IDF consensus criteria were enrolled in our study. Melatonin samples were taken at night (02:00 am- 03:00 am; light < 10 lux) and in the morning (08:00 am - 09:00 am). A morning venous blood was drawn after 8 hours of fasting. Serum glucose, total cholesterol, TG, HDL-cholesterol, and low-density lipoprotein (LDL) cholesterol levels were analyzed according to the manufacturer's original programs (Olympys AU 480, Beckman Coulter, USA). Serum melatonin concentrations were measured using ELISA kit (Elabscience Biotechnology Inc, China), serum ghrelin (ELISA kit, Elabscience Biotechnology Inc, China) and leptin (ELISA kit IBL-Hamburg, Germany) on Sirio S micro plate reader (SEAC, Italy). Each participant provided informed consent. All data were analysed by descriptive and nonparametric analysis. Statistical significance was accepted at P < 0.05.
Results: Women with TG ≥ 1.7 mmol/l did not have a statistically significant difference in age compared to women with TG < 1.7 mmol/l (t = 1.28, P = 0.209), in mean waist (t = 0.11, P = 0.916) and in mean BMI values (U = 154.50, P = 0.652). Women with TG ≥ 1.7 mmol/l have a higher average concentration of glucose and total cholesterol than women with TG < 1.7 mmol/l. The two subgroups did not differ in melatonin at 03:00am. and 08:00am and in other metabolic and hormonal parameters. Women with HDL-cholesterol < 1.3 mmol/l had a statistically significant larger waist (t = 3.45, P = 0.001) and higher BMI (U = 126.50, P = 0.029) and leptin at 08.00am (U = 134.00, P = 0.047), from women with HDL - cholesterol ≥ 1.3 mmol/l. The two subgroups did not differ in melatonin at 03:00 a. m and 8:00 a.m. and other hormonal and metabolic indicators.
Conclusion: Low HDL-cholesterol and elevated TG are associated with increased waist circumference, BMI and leptin, respectively, rather than with changes in the other investigated hormonal indicators.
References
Abood, Sattar J., Waleed K. Abdulsahib, Saad A. Hussain, and Sajida H. Ismail. (2020). Melatonin Potentiates the Therapeutic Effects of Metformin in Women with Metabolic Syndrome. Scientia Pharmaceutica 88,2: 28. https://doi.org/10.3390/scipharm88020028
Alberti, K. G., Zimmet, P., Shaw, J., & IDF Epidemiology Task Force Consensus Group (2005). The metabolic syndrome--a new worldwide definition. Lancet (London, England), 366(9491), 1059–1062. https://doi.org/10.1016/S0140-6736(05)67402-8
Al-Sarraf, I. A. K., Kasabri, V., Akour, A., & Naffa, R. (2018). Melatonin and cryptochrome 2 in metabolic syndrome patients with or without diabetes: a cross-sectional study. Hormone molecular biology and clinical investigation, 35(2), /j/hmbci.2018.35.issue-2/hmbci-2018-0016/hmbci-2018-0016.xml. https://doi.org/10.1515/hmbci-2018-0016
Cardinali DP, Bernasconi PAS, Reynoso R, Toso CFR, Scacchi P. (2013). Melatonin May Curtail the Metabolic Syndrome: Studies on Initial and Fully Established Fructose-Induced Metabolic Syndrome in Rats. InternationalJournal of Molecular Sciences. 14(2):2502-2514. https://doi.org/10.3390/ijms14022502
Claustrat, B., & Leston, J. (2015). Melatonin: Physiological effects in humans. Neuro-Chirurgie, 61(2-3), 77–84. https://doi.org/10.1016/j.neuchi.2015.03.002
Goyal, A., Terry, P. D., Superak, H. M., Nell-Dybdahl, C. L., Chowdhury, R., Phillips, L. S., & Kutner, M. H. (2014). Melatonin supplementation to treat the metabolic syndrome: a randomized controlled trial. Diabetology & metabolic syndrome, 6, 124. https://doi.org/10.1186/1758-5996-6-124
Hasan M.H. Al–Mhbashy; Hussain S. A.; Nawfal A.M. (2006) The Effects of Melatonin on The Oxidative
Stress, Protein Glycation, Microalbuminuria and Lipid Profile in Type II Diabetes MellitusIraqi J.Pharm.Sci., .15 (1), DOI: https://doi.org/10.31351/vol15iss1pp27-32
Koziróg, M., Poliwczak, A. R., Duchnowicz, P., Koter-Michalak, M., Sikora, J., & Broncel, M. (2011). Melatonin treatment improves blood pressure, lipid profile, and parameters of oxidative stress in patients with metabolic syndrome. Journal of pineal research, 50(3), 261–266. https://doi.org/10.1111/j.1600-079X.2010.00835.x
Li, Y., Sun, X., Wang, M., Jiang, Y., Ge, Q. Q., Li, T., Hou, Z., Shi, P., Yao, K., & Yin, J. (2024). Meta- analysis and machine learning reveal the antiobesity effects of melatonin on obese rodents. Obesity reviews: an official journal of the International Association for the Study of Obesity, e13701. Advance online publication. https://doi.org/10.1111/obr.13701
Mohammadi-Sartang, M., Ghorbani, M., & Mazloom, Z. (2018). Effects of melatonin supplementation on blood lipid concentrations: A systematic review and meta-analysis of randomized controlled trials. Clinical nutrition (Edinburgh,Scotland),37,1943–1954. https://doi.org/10.1016/j.clnu.2017.11.003
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) (2002). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 106(25), 3143–3421.
Partsernyak A.S., Polyakova V.O., Trufanov A.G., Medvedev D.S., Trotsyuk D.V., Markin K., Kurasov E.S., Kuznetsova E.V., Krasichkov A.S. (2022). Melatonin: Manager of psychosomatic and metabolic disorders in polymorbid cardiovascular pathology. Front Neurosci 16:989497. doi: 10.3389/fnins.2022.989497
Saklayen M. G. (2019). The Global Epidemic of the Metabolic Syndrome. Current hypertension reports, 20(2), 12. https://doi.org/10.1007/s11906-018-0812-z
Santos-Ledo, A.; Luxán-Delgado, B.d.; Caballero, B.; Potes, Y.; Rodríguez-González, S.; Boga, J.A.; Coto-
Montes, A.; García-Macia, M. (2021).Melatonin Ameliorates Autophagy Impairment in a Metabolic
Syndrome Model. Antioxidants, 10, 796. https://doi.org/10.3390/antiox10050796
Söylemez S, Sivri ABÇ, Şimşek E, Polat B, Çakır B. (2019). Melatonin, leptin, and ghrelin levels in nurses working night shifts. J Surg Med. 3(1):22-26. https://doi.org/10.28982/josam.443902
Zimmet, P., Magliano, D., Matsuzawa, Y., Alberti, G., & Shaw, J. (2005). The metabolic syndrome: a global public health problem and a new definition. Journal of atherosclerosis and thrombosis, 12(6), 295–300. https://doi.org/10.5551/jat.12.295
